中国医科大学学报  2021, Vol. 50 Issue (9): 769-773

文章信息

姜红, 姜红堃
JIANG Hong, JIANG Hongkun
血清胱抑素C对川崎病及其合并冠状动脉损害的诊断价值
The diagnostic value of serum cystatin C in Kawasaki disease and its concomitant coronary artery lesion
中国医科大学学报, 2021, 50(9): 769-773
Journal of China Medical University, 2021, 50(9): 769-773

文章历史

收稿日期:2020-11-13
网络出版时间:2021-09-09 12:04
血清胱抑素C对川崎病及其合并冠状动脉损害的诊断价值
姜红 , 姜红堃     
中国医科大学附属第一医院儿科, 沈阳 110001
摘要目的 探讨血清胱抑素C(Cys-C)对川崎病(KD)及其合并冠状动脉损害(CAL)的诊断价值。方法 收集2010年1月至2019年10月中国医科大学附属第一医院儿科就诊的157例急性期KD患儿(KD组)及200例健康儿童(对照组)的临床资料。根据超声心动图检查结果将KD患儿分为合并冠状动脉损害组(CAL组,123例)与未合并冠状动脉损害组(NCAL组,34例),比较2组患儿血清Cys-C、尿素氮(BUN)、肌酐(Cr)水平。同时根据Cys-C水平将KD患儿分为Cys-C高值组与Cys-C正常组,比较2组丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)的差异。绘制血清Cys-C预测KD及其合并CAL的受试者工作特征(ROC)曲线,分析曲线下面积(AUC)及不同界点的临床诊断价值。结果 KD组血清Cys-C值明显高于对照组(P < 0.05)。Cys-C高值组与Cys-C正常组间ALT、AST水平比较未见统计学差异(均P>0.05)。CAL组血清Cys-C值明显高于NCAL组(P < 0.01)。Cys-C预测KD及其合并CAL的ROC曲线的AUC分别为0.600、0.821;最佳界值分别为0.795 mg/L及0.845 mg/L。结论 血清Cys-C可能对于KD具有一定的辅助诊断价值,KD急性期血清Cys-C对KD合并CAL具有预测价值。
关键词川崎病    胱抑素C    冠状动脉损害    诊断价值    
The diagnostic value of serum cystatin C in Kawasaki disease and its concomitant coronary artery lesion
Department of Pediatrics, The First Hospital of China Medical University, Shenyang 110001, China
Abstract: Objective To evaluate the diagnostic value of serum cystatin C (Cys-C) in Kawasaki disease (KD) and its complication, coronary artery lesion (CAL). Methods Clinical data were collected from 157 children in the acute stage of KD (KD group) and 200 healthy children (control group) admitted to the Department of Pediatrics of the First Hospital of China Medical University from January 2010 to October 2019. According to the results of echocardiography, the children with KD were divided into two groups: a group with CAL (CAL group, 123 cases) and a group without CAL (NCAL group, 34 cases). The levels of serum Cys-C, urea nitrogen (BUN), and creatinine (Cr) in each group were compared. At the same time, children with KD were divided into two groups according to Cys-C level: a high Cys-C group and a normal Cys-C group, and the alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were compared between the two groups. Receiver operator characteristic (ROC) curves for serum Cys-C for predicting KD and its combination with CAL were constructed, and the area under the curve (AUC) and the clinical diagnostic values of different boundary points were analyzed. Results The serum Cys-C levels in the KD group were significantly higher than those in the control group (P < 0.05). There were no significant differences in ALT and AST levels between the high Cys-C group and the normal Cys-C group (P>0.05). The serum Cys-C levels in the CAL group were significantly higher than those in the NCAL group (P < 0.01). The AUC of the Cys-C-predicted ROC curve of KD alone and combined with CAL were 0.600 and 0.821, respectively. The optimal cut-off points were 0.795 mg/L and 0.845 mg/L, respectively. Conclusion Serum Cys-C may have some auxiliary diagnostic value for KD, and serum Cys-C in the acute stage of KD has predictive value for KD complicated with CAL.

川崎病(Kawasaki disease,KD) 临床上又称为皮肤黏膜淋巴结综合征,是一种发生于5岁以下婴幼儿的急性自限性全身性血管炎,是发达国家儿童急性血管炎及获得性心脏病的主要病因[1]。KD在世界各地不同种族的儿童中均有发现,以东北亚国家的发病率最高。研究[2]显示我国KD发病率呈上升趋势。KD最主要的后遗症为冠状动脉损害(coronary artery lesion,CAL) 与冠状动脉瘤形成,是导致患儿死亡的首要原因[3]。KD的诊断依据非特异性临床表现,因此易漏诊误诊,若患儿未得到及时治疗,可导致CAL的发生风险增加[4]。胱抑素C (cystatin C,Cys-C) 属于半胱氨酸蛋白酶抑制剂2型半胱氨酸蛋白酶超家族成员,是由122个氨基酸组成分子量为13.3×103的非糖基化的碱性蛋白质[5]。血清Cys-C是经典的监控肾功能的生物学标志物,可预测心血管疾病、癌症、肝脏损伤等[6-7]。本研究分析KD患儿血清Cys-C水平,探讨血清Cys-C对KD及KD合并CAL的诊断价值。

1 材料与方法 1.1 临床资料及分组

收集2010年1月至2019年10月间于中国医科大学附属第一医院儿科就诊的157例KD急性期患儿(KD组) 的临床资料,包括年龄、性别、血清Cys-C、尿素氮(blood urea nitrogen,BUN)、肌酐(creatinine,Cr)、丙氨酸转氨酶(alanine transaminase,ALT)、天冬氨酸转氨酶(aspartate aminotransferase,AST)。KD组纳入标准:(1) 综合患儿病史、临床症状指征、影像学检查等资料,符合KD诊断标准[8];(2) 患儿发热1~2周内;(3) 临床资料完整。排除标准:(1) 合并低血流量休克;(2) 合并明确由其他疾病所导致的肝肾损害;(3) 合并先天性心脏病、心肌病;(4) 入院前已接受静脉注射丙种球蛋白、阿司匹林等治疗;(5) 病例资料缺失。其中男101例,女56例,年龄2个月~8岁,中位年龄为[2.00 (1.00~4.00)]岁。依据超声心动图CAL诊断标准[9],具体包括:年龄 < 36个月,冠状动脉直径≥2.5 mm;年龄36个月~ < 108个月,冠状动脉直径≥3 mm;年龄≥108个月,冠状动脉直径≥3.5 mm。合并CAL患儿为CAL组(n = 34),其中,冠状动脉扩张(coronary artery ectasia,CAE) 31例,冠状动脉瘤3例;未合并CAL患儿为NCAL组(n = 123)。又根据Cys-C水平(参考区间0.53~0.95 mg/L)分组:>0.95 mg/L患儿为Cys-C高值组(n = 23);≤0.95 mg/L患儿为Cys-C正常组(n = 134)。

同时选取此期间门诊就诊的健康体检儿童200例为对照组,其中男105例,女95例,年龄2个月~8岁,中位年龄[5.00 (3.00~6.00)]岁。

1.2 血清Cys-C、BUN、Cr、ALT、AST测定

受试者空腹至少3~4 h后采集静脉血(2~3 mL),应用日立7600-110全自动生化分析仪采用颗粒增强透射免疫比浊法测定血清Cys-C浓度;尿素酶法测血清BUN浓度;肌氨酸氧化酶法测定血清Cr浓度。应用Olympus AU-5400型全自动生化分析仪检测ALT、AST水平。

1.3 超声心动图检查

应用GE公司Vivid Dimension彩色超声诊断仪行超声心动图检查,重点显示左冠状动脉主干、左前降支、左回旋支、右冠状动脉及后降支冠状动脉图像。KD病程45 d内,每周1次超声心动图检查,然后每月检查1次,至第3个月末。

1.4 统计学分析

采用SPSS 25.0软件进行统计学分析,正态分布计量资料采用x±s表示,组间比较采用t检验;不符合正态分布的计量资料用M (P25~P75) 表示,组间比较采用Mann-Whitney U检验。绘制Cys-C预测KD及其合并CAL的受试者工作特征(receiver operator characteristic,ROC) 曲线,分析曲线下面积(area under the curve,AUC) 及不同界点的诊断价值,确定血清Cys-C值最佳界值,P < 0.05为差异有统计学意义。

2 结果 2.1 KD组与对照组临床指标比较

结果显示,与对照组比较,KD组血清Cys-C值明显增高(P < 0.05)。BUN与Cr水平明显降低(P < 0.01)。2组年龄差异有统计学意义(P < 0.01),表 1

表 1 KD组与对照组临床指标比较[M(P25~P75)] Tab.1 Comparison of clinical indicators between KD group and control group [M(P25~P75)]
Group n Age (year) Cys-C (mg/L) BUN (mmol/L) Cr (mmol/L)
Control 200 5.00(3.00-6.00) 0.73(0.67-0.79) 4.15(3.32-4.74) 29.00(24.00-33.75)
KD 157 2.00(1.00-4.00) 0.78(0.69-0.87) 2.61(1.96-3.18) 23.00(19.00-28.00)
Z -8.618 -3.245 -11.535 -7.041
P < 0.001 0.010 < 0.001 < 0.001
Cys-c, cystatin C, BUN, blood urea nitrogen; Cr, creatine.

2.2 Cys-C高值组与Cys-C正常组ALT、AST比较

结果显示,2组ALT、AST水平比较无统计学差异(均P > 0.05)。见表 2

表 2 Cys-C高值组与Cys-C正常组ALT、AST水平比较[M(P25~P75), IU/L] Tab.2 Comparison of ALT and AST levels between the high Cys-C group and the normal Cys-C group [M(P25-P75), IU/L]
Group n ALT AST
High Cys-C 23 31.00(14.00-43.00) 26.00(16.00-44.00)
Normal Cys-C 134 21.00(11.00-64.25) 26.00(19.00-36.00)
Z -0.236 -0.084
P 0.814 0.933
ALT, alanine transaminase; AST, aspartate aminotransferase.

2.3 CAL组与NCAL组血清Cys-C、BUN、Cr水平比较

结果显示,CAL组血清Cys-C明显高于NCAL组(P < 0.001);而2组血清BUN和Cr比较无统计学差异(均P > 0.05),见表 3

表 3 CAL组与NCAL组血清Cys-C、BUN、Cr水平比较(x±s) Tab.3 Comparison of serum Cys-c, BUN, and Cr between the CAL and NCAL groups (x±s)
Group n Cys-C (mg/L) BUN (mmol/L) Cr (mmol/L)
CAL 34 0.95±0.18 2.79±0.97 24.00(19.00-27.00)
NCAL 123 0.75±0.11 2.62±0.93 23.00(19.00-28.00)
t/Z 12.334 0.632 -0.400
P < 0.001 0.363 0.968

2.4 血清Cys-C预测KD及KD合并CAL的ROC曲线分析

结果显示,Cys-C预测KD及KD合并CAL的ROC曲线AUC分别为0.600和0.821;预测的最佳界值分别为0.795 mg/L、0.845 mg/L。见表 4图 12

表 4 Cys-C预测KD及其合并CAL的ROC曲线分析 Tab.4 ROC curve analysis of Cys-C predicting KD and combined CAL
Item AUC SE P 95% CI Cut-off (mg/L) Sensitivity (%) Specificity (%)
KD 0.600 0.031 0.001 0.540-0.660 0.795 46.5 76.5
CAL 0.821 0.044 < 0.001 0.735-0.907 0.845 61.8 89.4

图 1 血清Cys-C预测KD的ROC曲线 Fig.1 Curve of serum Cys-C predicting KD

图 2 血清Cys-C预测KD合并CAL的ROC曲线 Fig.2 Curve of serum Cys-C predicting KD combined with CAL

3 讨论

自1967年川崎首次报道KD以来,学者们对KD的认识日益完善[1-3]。KD属于感染性疾病与自身免疫性疾病,疾病进展依赖于感染触发、遗传易感性、宿主及环境影响等多种因素[2, 10]。目前,KD确切病理生理机制尚未明确[10-11]。KD初期治疗主要为静脉注射免疫球蛋白及口服阿司匹林。研究[11-12]显示,若未接受常规治疗,25%KD患儿会发生CAL,包括心肌梗死、CAE、冠状动脉瘘及冠状动脉瘤等[11-12]。因此,找到早期诊断KD及其合并CAL的生物学标志物非常重要。

Cys-C的编码基因是CST3管家基因,位于20 pl1.21,在有核细胞中均有表达。Cys-C以相对恒定的速率产生并分泌到各种生物体液中,通过肾小球的滤过作用从血浆中去除,再由近端小管重新吸收降解[13]。Cys-C的功能与其靶酶密切相关,它既可特异性调节半胱氨酸蛋白酶活性,也可调节其他重要的生物学功能(细胞增殖、细胞分化、细胞迁移、免疫调节等) [14]

本研究结果显示,KD组血清Cys-C值明显高于对照组,而血清BUN与Cr明显低于对照组(均P < 0.01)。研究[15-16]显示血清BUN、Cr受年龄因素影响,本研究中对照组年龄高于KD组,推测为KD组血清BUN与Cr明显低于对照组的原因。AL MUSAIMII等[17]研究发现年龄、性别等因素对血清Cys-C无影响,本研究中KD组血清Cys-C值明显高于对照组,因此推测血清Cys-C可能对KD具有诊断价值。JIA等[18]发现组织蛋白酶B在KD的组织炎症过程中发挥关键作用。本研究中KD组血清Cys-C高于对照组,可能与组织蛋白酶B、H等参与KD炎症反应,导致Cys-C与半胱氨酸蛋白酶平衡失调,继而使血清Cys-C水平升高有关。

有研究[7, 19]表明,肝功能损伤是KD急性期的常见并发症,且肝功能损伤可能导致血清Cys-C升高。为排除肝功能异常对Cys-C的影响,本研究比较了Cys-C高值组与Cys-C正常组肝功能相关指标,结果发现2组ALT、AST无统计学差异(P > 0.05),表明本研究中Cys-C水平增高与肝功能损伤无关。绘制血清Cys-C预测KD的ROC曲线发现AUC为0.600,最佳界值为0.795 mg/L,认为Cys-C可能对KD具有一定的预测价值。

本研究结果显示,KD患儿CAL组较NCAL组血清Cys-C水平增高(P < 0.05),推测KD患儿急性期血清Cys-C水平增高对KD合并CAL具有预测价值。本研究34例CAL患儿中31例CAE,这与YETKIN等[20]提出冠状动脉粥样硬化性心脏病合并CAE患者血清Cys-C水平明显增高的结论相似。GUPTA-MALHOTRA等[21]对17例KD急性期血清Cys-C研究发现,KD血清Cys-C在急性期低于对照组,考虑可能的原因包括:(1) 种族差异;(2) 样本量不同;(3) 研究对象不同,本研究对照组为儿童,而GUPTA-MALHOTRA等研究的对照组包括儿童及成人。ROC曲线分析结果显示,当血清Cys-C浓度为0.845 mg/L时,约登指数达到峰值,灵敏度和特异度分别为61.8%、89.4%,可见血清Cys-C对CAL具有较高的预测效能。

研究[10-11]表明,KD的两个重要病理机制是炎症反应及内皮细胞损伤,并涉及先天免疫及适应性免疫的激活。另有研究[22-23]表明,血清Cys-C与炎症及血管重建过程密切相关,在先天性免疫和自身免疫性疾病中发挥重要作用。因此推测血清Cys-C在KD的组织炎症及免疫机制中同时发挥作用,但具体作用机制尚需进一步研究论证。

综上所述,血清Cys-C水平可能对于KD具有一定的辅助诊断价值,对KD合并CAL具有预测价值。今后将采取多中心、大样本研究以期更加准确找到可预测儿童KD及发生CAL的Cys-C界值。

参考文献
[1]
PORRITT RA, MARKMAN JL, MARUYAMA D, et al. Interleukin-1 beta-mediated sex differences in Kawasaki disease vasculitis development and response to treatment[J]. Arterioscler Thromb Vasc Biol, 2020, 40(3): 802-818. DOI:10.1161/ATVBAHA.119.313863
[2]
ELAKABAWI K, LIN J, JIAO F, et al. Kawasaki disease: global burden and genetic background[J]. Cardiol Res, 2020, 11(1): 9-14. DOI:10.14740/cr993
[3]
KIM HJ, KIM JJ, YUN SW, et al. Association of the IL16 Asn1147Lys polymorphism with intravenous immunoglobulin resistance in Kawasaki disease[J]. J Hum Genet, 2020, 65(4): 421-426. DOI:10.1038/s10038-020-0721-2
[4]
MARRANI E, BURNS JC, CIMAZ R. How should we classify Kawasaki disease?[J]. Front Immunol, 2018, 9: 2974. DOI:10.3389/fimmu.2018.02974
[5]
FERNANDO S, POLKINGHORNE KR. Cystatin C: not just a marker of kidney function[J]. J Brasileiro De Nefrologia, 2020, 42(1): 6-7. DOI:10.1590/2175-8239-JBN-2019-0240
[6]
MAO Q, ZHAO N, WANG Y, et al. Association of cystatin C with metabolic syndrome and its prognostic performance in non-ST-segment elevation acute coronary syndrome with preserved renal function[J]. Biomed Res Int, 2019, 2019: 8541402. DOI:10.1155/2019/8541402
[7]
ICHIKAWA T, MIYAAKI H, MIUMA S, et al. Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease[J]. Biomed Rep, 2020, 12(3): 89-98. DOI:10.3892/br.2020.1273
[8]
NEWBURGER JW, TAKAHASHI M, GERBER MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Circulation, 2004, 110(17): 2747-2771. DOI:10.1161/01.CIR.0000145143.19711.78
[9]
FU S, GONG F, XIE C, et al. S100A12 on circulating endothelial cells surface in children with Kawasaki disease[J]. Pediatr Res, 2010, 68(2): 165-168. DOI:10.1203/pdr.0b013e3181e67ce8
[10]
BELKAIBECH S, POTTER BJ, KANG H, et al. Maternal autoimmune disorders and risk of Kawasaki disease in offspring[J]. J Pediatr, 2020, 222: 240-243. DOI:10.1016/j.jpeds.2020.02.016
[11]
QIAN BY, HUANG H, CHENG MY, et al. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury[J]. Eur J Med Res, 2020, 25(1): 8. DOI:10.1186/s40001-020-00406-5
[12]
WANG Y, HU J, LIU J, et al. The role of Ca2+/NFAT in dysfunction and inflammation of human coronary endothelial cells induced by sera from patients with Kawasaki disease[J]. Sci Rep, 2020, 10(1): 4706. DOI:10.1038/s41598-020-61667-y
[13]
MOHD TAHIR NA, MOHD SAFFIAN S, ISLAHUDIN FH, et al. Effects of CST3 gene G73A polymorphism on cystatin C in a prospective multiethnic cohort study[J]. Nephron, 2020, 144(4): 204-212. DOI:10.1159/000505296
[14]
CARLESSON E, SUPHARATTANASITTHI W, JACKSON M, et al. Increased rate of retinal pigment epithelial cell migration and pro-angiogenic potential ensuing from reduced cystatin C expression[J]. Invest Ophthalmol Vis Sci, 2020, 61(2): 9. DOI:10.1167/iovs.61.2.9
[15]
PENG X, LV Y, FENG G, et al. Algorithm on age partitioning for estimation of reference intervals using clinical laboratory database exemplified with plasma creatinine[J]. Clin Chem Lab Med, 2018, 56(9): 1514-1523. DOI:10.1515/cclm-2017-1095
[16]
LIU Q, WANG Y, CHEN Z, et al. Age- and sex-specific reference intervals for blood urea nitrogen in Chinese general population[J]. Sci Rep, 2021, 11(1): 10058. DOI:10.1038/s41598-021-89565-x
[17]
AL MUSAIMI O, ABU-NAWWAS AH, AL SHAER D, et al. Influence of age, gender, smoking, diabetes, thyroid and cardiac dysfunctions on cystatin C biomarker[J]. Semergen, 2019, 45(1): 44-51. DOI:10.1016/j.semerg.2018.07.005
[18]
JIA C, ZHANG J, CHEN H, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation[J]. Cell Death Dis, 2019, 10(10): 778. DOI:10.1038/s41419-019-2021-3
[19]
MAMMADOV G, LIU HH, CHEN WX, et al. Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities[J]. Clin Exp Med, 2020, 20(1): 21-30. DOI:10.1007/s10238-019-00596-1
[20]
YETKIN E, ACIKGOZ N, SIVRI N, et al. Increased plasma levels of cystatin C and transforming growth factor-beta1 in patients with coronary artery ectasia: can there be a potential interaction between cystatin C and transforming growth factor-beta1[J]. Coron Artery Dis, 2007, 18(3): 211-214. DOI:10.1097/MCA.0b013e328087bd98
[21]
GUPTA-MALHOTRA M, LEVINE DM, COOPER RS, et al. Decreased levels of cystatin C, an inhibitor of the elastolytic enzyme cysteine protease, in acute and subacute phases of Kawasaki disease[J]. Cardiology, 2003, 99(3): 121-125. DOI:10.1159/000070668
[22]
ZHANG W, ZI M, SUN L, et al. Cystatin C regulates major histocompatibility complex-Ⅱ-peptide presentation and extracellular signal-regulated kinase-dependent polarizing cytokine production by bone marrow-derived dendritic cells[J]. Immunol Cell Biol, 2019, 97(10): 916-930. DOI:10.1111/imcb.12290
[23]
LARSEN TR, GERKE O, DIEDERICHSEN ACP, et al. Lack of association between cystatin C and different coronary atherosclerotic manifestations[J]. Scand J Clin Lab Invest, 2017, 77(8): 574-581. DOI:10.1080/00365513.2017.1355980